Sangamo Therapeutics Inc at Bank of America Merrill Lynch Health Care Conference Transcript
Thank you so much for joining us today at the Bank of America Merrill Lynch health care conference here. Today it's my pleasure to have Sandy Macrae, the CEO from Sangamo, a leader in gene therapy and gene editing. And we're all looking forward to the discussion.
Absolutely, nice to be here.
Questions & Answers
Yes. So obviously, Sangamo has been in the gene editing field for quite a while. And can you broadly talk through the evolution of your technology for the past few years and given that there is interest arising over the gene therapy and gene editing field overall? And can you also speak to the editing efficiency as well as a safety comparing to your other emerging technology as well such as CRISPR and maybe RCUS, and maybe some more recently talking about non-nucleus edited probe technologies?
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
